Friday 6 November 2026 Export BIIB’s income statement to Excel — free account

Biogen Inc.

BIIB Healthcare Drug Manufacturers General

Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024.

Revenue: +10.6%
EPS: −104.4%
Free cash flow: −69.3%
Total debt: +16.0%

Quarter to September 2026, against a year earlier

248.66 4.73 +1.94%

Follow BIIB

Alert me

Market cap: $36.1B
P/E: 104×
Fwd P/E: 47.4×
Dividend yield: —
F-score: 4/9
Altman Z: 3.13
Beneish M: −2.67
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Biogen Inc. (BIIB) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Biogen Inc. (BIIB) trades at a price to free cash flow of 21.3×. Over the past ten years it has ranged from 0.0× (September 2015) to 37.8× (October 2023); the current reading is higher than 77% of that period. That is in line with the Drug Manufacturers General industry median of 21.3× and in line with the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/BIIB/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Biogen Inc. price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/BIIB/metrics/price-to-free-cash-flow">Biogen Inc. (BIIB) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	12.8×	44.27%
FY2024	8.9×	(71.77%)
FY2023	31.3×	36.40%
FY2022	23.0×	116.05%
FY2021	10.6×	(0.70%)
FY2020	10.7×	23.66%
FY2019	8.7×	(25.52%)
FY2018	11.6×	(57.63%)
FY2017	27.4×	77.59%
FY2016	15.5×	(29.30%)

Period	Price to free cash flow	Change
Sep 2026	19.7×	56.83%
Jun 2026	12.6×	11.80%
Mar 2026	11.2×	(11.99%)
Dec 2025	12.8×	40.65%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 37.8×

Ten-year median 13.4×

Current reading's percentile 77

Company	Price to free cash flow
SNY Sanofi compare	6.7×
GSK GSK PLC Sponsored ADR compare	11.4×
BMY Bristol Myers Squibb Company compare	13.9×
GILD Gilead Sciences, Inc. compare	15.1×
PFE Pfizer Inc. compare	15.5×
BIIB Biogen Inc.	21.3×
NVO Novo Nordisk A/S compare	23.5×
AMGN Amgen Inc. compare	27.3×
AZN AstraZeneca PLC compare	45.8×
Drug Manufacturers General industry median	21.3×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Biogen Inc. (BIIB) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on BIIB

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on BIIB

Stockrow Weekly